Gossamer Bio

Phase III Trials And Global Collaborations Will Expand Treatment Horizons

AnalystConsensusTarget

Not Invested

Consensus Narrative from 7 Analysts

Published

18 May 25

AnalystConsensusTarget's Fair Value

US$7.75

65.7% undervalued

04 Sep

US$2.66

186.0%

7.7%

186.0%

7.7%

Edit anytime before May 18 8:14 PM. Then post Updates to your followers.

Author's Valuation

US$7.8

65.7% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates0

AnalystConsensusTarget Fair Value

US$7.8

65.7% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

49.87%

Biotech revenue growth rate

7.59%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.18%

Calculation

US$27.82m

Earnings '28

78.56x

PE Ratio '28

US$2.19b

Market Cap '28

US$2.19b

Market Cap '28

229.73m

No. shares '28

US$9.51

Share Price '28

US$9.51 Share Price '28

Discounted to 2025 @ 7.18% p.a.

US$7.73

Fair Value '25